LoginSign Up
Voyager Therapeutics

Voyager Therapeutics

Voyager Therapeutics is a biotechnology company founded in 2014 that is headquartered in Cambridge, Massachusetts developing gene therapies to treat neurological disorders.

Voyager Therapeutics is a biotechnology company that is headquartered in Cambridge, Massachusetts that was founded by Guangping Gao, Krystof Bankiewicz, Mark Kay, and Phillip D. Zamore in 2014. The company is developing novel gene therapies using the adeno-associated virus (AAV) for the treatment of neurological disorders such as Parkinson's disease, amyotrophic lateral sclerosis (ALS), Friedreich's ataxia, Huntington's disease, and Alzheimer's disease.

Funding

Corporate round

On February 11, 2015 Voyager Therapeutics announced they raised $30 million in their corporate funding round from Genzyme.

Series A

On February 12, 2014 Voyager Therapeutics closed their series A funding round with $45 million in funding from Third Rock Ventures.

Series B

On April 13, 2015 Voyager Therapeutics closed their series B funding round with $60 million in funding from Wellington Management, Partner Fund Management, Fidelity Management and Research Company, Casdin Capital, and Brookside Capital.

Timeline

People

Name
Role
Related Golden topics

Further reading

Title
Author
Link
Type

Voyager Therapeutics Receives FDA Guidance on Development Path for VY-AADC for Parkinson's Disease and Provides Clinical Update

Global News Wire

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References